Avodart

Avodart is a brand name of dutasteride, approved by the FDA in the following formulation(s):

AVODART (dutasteride - capsule; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: November 20, 2001
  
  Strength(s): 0.5MG ^[RLD][AB]

Has a generic version of Avodart been approved?

A generic version of Avodart has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Avodart and have been approved by the FDA:

dutasteride capsule; oral

• 
  Manufacturer: BARR
  
  Approval date: December 21, 2010
  
  Strength(s): 0.5MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Avodart. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Androstenone derivative
  Patent 5,565,467
  Issued: October 15, 1996
  Inventor(s): Batchelor; Kenneth W. & Frye; Stephen V. & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
  Assignee(s): Glaxo Wellcome Inc.
  The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
  
  Patent expiration dates:
  
  
  • November 20, 2015
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Androstenone derivative
  Patent 5,846,976
  Issued: December 8, 1998
  Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
  Assignee(s): Glaxo Wellcome Inc.
  The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
  
  Patent expiration dates:
  
  
  • September 17, 2013
    
    ✓ 
    Patent use: METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
  
  



• 
  Androstenones
  Patent 5,998,427
  Issued: December 7, 1999
  Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon
  Assignee(s): Glaxo Wellcome Inc.
  The present invention relates to compounds of formula (I), wherein carbons 1 and 2 are joined by either a single or a double bond; R.sup.1 is hydrogen or methyl; R.sup.2 is hydrogen or methyl; R.sup.3 is (B) wherein X, R.sup.6, R.sup.7 and R.sup.8 are various groups, and pharmaceutically acceptable solvates thereof and their use in the treatment of androgen responsive and mediated diseases. ##STR1##
  
  Patent expiration dates:
  
  
  • September 17, 2013
    
    ✓ 
    Patent use: METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 19, 2011 - USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
  
  

See also...

• Avodart Consumer Information (Drugs.com)
• Avodart Consumer Information (Wolters Kluwer)
• Avodart Consumer Information (Cerner Multum)
• Avodart Advanced Consumer Information (Micromedex)
• Avodart AHFS DI Monographs (ASHP)
• Dutasteride Consumer Information (Wolters Kluwer)
• Dutasteride Consumer Information (Cerner Multum)
• Dutasteride Advanced Consumer Information (Micromedex)
• Dutasteride AHFS DI Monographs (ASHP)

Vastcillin

Vastcillin may be available in the countries listed below.

Ingredient matches for Vastcillin

Ciclacillin

Ciclacillin is reported as an ingredient of Vastcillin in the following countries:

• Japan

International Drug Name Search

Trichomonacid

Trichomonacid may be available in the countries listed below.

Ingredient matches for Trichomonacid

Metronidazole

Metronidazole is reported as an ingredient of Trichomonacid in the following countries:

• Bulgaria


• Georgia

International Drug Name Search

Alsidol

Alsidol may be available in the countries listed below.

Ingredient matches for Alsidol

Omeprazole

Omeprazole is reported as an ingredient of Alsidol in the following countries:

• Italy

International Drug Name Search

Elidel

Elidel is a brand name of pimecrolimus topical, approved by the FDA in the following formulation(s):

ELIDEL (pimecrolimus - cream; topical)

• 
  Manufacturer: VALEANT INTL
  
  Approval date: December 13, 2001
  
  Strength(s): 1% ^[RLD]

Has a generic version of Elidel been approved?

No. There is currently no therapeutically equivalent version of Elidel available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Elidel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Heteroatoms-containing tricyclic compounds
  Patent 5,912,238
  Issued: June 15, 1999
  Inventor(s): Baumann; Karl & Emmer; Gerhard
  Assignee(s): Novartis AG
  The invention concerns the compounds of formula I ##STR1## wherein the substituents have various significances. They are prepared by several processes including epimerizing replacement, treatment with cyanogen bromide or thiophosgene, treatment with an acid having a non-nucleophilic anion, treatment with dimethylsulfoxide and acetic anhydride, acylation, treatment with an oxalyl derivative and ammonia, methylation, oxidation, deprotection and protection. They possess interesting pharmacological activity as antiinflammatory, immunosuppressant, antiproliferative and chemotherapeutic drug resistance reversing agents.
  
  Patent expiration dates:
  
  
  • June 15, 2016
    
  
  
  
  • December 15, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical compositions
  Patent 6,352,998
  Issued: March 5, 2002
  Inventor(s): Martin; Jackman & Xue-Ping; Popp & Friedrich; Richter & Fritz; Schmook
  Assignee(s): Novartis AG
  This invention provides a topical composition, in the form of an emulsion, that comprises a compound of the FK506 class; a physiologically acceptable alkanediol, ether diol or diether alcohol containing up to 8 carbon atoms as solvent for the compound of the FK506 class; an unsaturated fatty alcohol and water. In another aspect, this invention provides a topical pharmaceutical composition that comprises a macrolide in suspension. In a further aspect, this invention provides the use of an unsaturated fatty alcohol to stabilize a macrolide in a pharmaceutical composition.
  
  Patent expiration dates:
  
  
  • October 26, 2015
    
  
  
  
  • April 26, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Crystalline macrolides and process for their preparation
  Patent 6,423,722
  Issued: July 23, 2002
  Inventor(s): Cornelia; Dosenbach & Maximilian; Grassberger & Otto; Hartmann & Amarylla; Horvath & Jean-Paul; Mutz & Gerhard; Penn & Sabine; Pfeffer & Dierk; Wieckhusen
  Assignee(s): Novartis AG
  33-Epichloro-33-desoxyascomycin of formula I and various tautomeric or forms thereof, in crystalline form, such as Form A and Form B. Their preparation involves appropriately converting amorphous compound of formula I, or compound of formula I in other than Form A, or compound of formula I in other than Form B, respectively, from a solution thereof under crystallization-inducing conditions or conditions inducing preferential crystallization of Form A or B, respectively. Such crystals are particularly indicated for use in the preparation of topical galenical forms of the compound for pharmaceutical use, e.g. creams, emulsions and ointments.
  
  Patent expiration dates:
  
  
  • June 26, 2018
    
  
  
  
  • December 26, 2018
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Elidel Consumer Information (Drugs.com)
• Elidel Consumer Information (Wolters Kluwer)
• Elidel Consumer Information (Cerner Multum)
• Elidel Topical Advanced Consumer Information (Micromedex)
• Elidel AHFS DI Monographs (ASHP)
• Pimecrolimus Consumer Information (Wolters Kluwer)
• Pimecrolimus topical Consumer Information (Cerner Multum)
• Pimecrolimus Topical Advanced Consumer Information (Micromedex)
• Pimecrolimus AHFS DI Monographs (ASHP)

Eau oxygénée 10 volumes Evolupharm

Eau oxygénée 10 volumes Evolupharm may be available in the countries listed below.

Ingredient matches for Eau oxygénée 10 volumes Evolupharm

Hydrogen Peroxide

Hydrogen Peroxide 3 percent (a derivative of Hydrogen Peroxide) is reported as an ingredient of Eau oxygénée 10 volumes Evolupharm in the following countries:

• France

International Drug Name Search

Rythmol

See also: Generic Rythmol SR

Rythmol is a brand name of propafenone, approved by the FDA in the following formulation(s):

RYTHMOL (propafenone hydrochloride - tablet; oral)

• 
  Manufacturer: GLAXOSMITHKLINE LLC
  
  Approval date: November 27, 1989
  
  Strength(s): 150MG ^[AB], 300MG ^[RLD][AB]


• 
  Manufacturer: GLAXOSMITHKLINE LLC
  
  Approval date: November 20, 1992
  
  Strength(s): 225MG ^[AB]

Has a generic version of Rythmol been approved?

Yes. The following products are equivalent to Rythmol:

propafenone hydrochloride tablet; oral

• 
  Manufacturer: MUTUAL PHARM
  
  Approval date: November 29, 2001
  
  Strength(s): 150MG ^[AB], 225MG ^[AB], 300MG ^[AB]


• 
  Manufacturer: NESHER PHARMS
  
  Approval date: February 7, 2002
  
  Strength(s): 150MG ^[AB], 225MG ^[AB], 300MG ^[AB]


• 
  Manufacturer: PLIVA
  
  Approval date: April 23, 2004
  
  Strength(s): 150MG ^[AB], 225MG ^[AB], 300MG ^[AB]


• 
  Manufacturer: VINTAGE PHARMS
  
  Approval date: October 17, 2002
  
  Strength(s): 150MG ^[AB], 225MG ^[AB], 300MG ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: October 24, 2000
  
  Strength(s): 150MG ^[AB], 225MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rythmol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Rythmol.

See also...

• Rythmol Consumer Information (Wolters Kluwer)
• Rythmol Consumer Information (Cerner Multum)
• Rythmol Advanced Consumer Information (Micromedex)
• Rythmol AHFS DI Monographs (ASHP)
• Propafenone Consumer Information (Wolters Kluwer)
• Propafenone Sustained-Release Capsules Consumer Information (Wolters Kluwer)
• Propafenone Consumer Information (Cerner Multum)
• Propafenone Advanced Consumer Information (Micromedex)
• Propafenone Hydrochloride AHFS DI Monographs (ASHP)

Lodosyn

Lodosyn is a brand name of carbidopa, approved by the FDA in the following formulation(s):

LODOSYN (carbidopa - tablet; oral)

• 
  Manufacturer: ATON
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 25MG ^[RLD]

Has a generic version of Lodosyn been approved?

No. There is currently no therapeutically equivalent version of Lodosyn available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lodosyn. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Lodosyn.

See also...

• Lodosyn Consumer Information (Wolters Kluwer)
• Lodosyn Consumer Information (Cerner Multum)
• Carbidopa Consumer Information (Wolters Kluwer)
• Carbidopa Consumer Information (Cerner Multum)

Agomélatine

Agomélatine may be available in the countries listed below.

Ingredient matches for Agomélatine

Agomelatine

Agomélatine (DCF) is also known as Agomelatine (Rec.INN)

International Drug Name Search

Glossary

DCF	Dénomination Commune Française
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Dépo-Prodasone

Dépo-Prodasone may be available in the countries listed below.

Ingredient matches for Dépo-Prodasone

Medroxyprogesterone

Medroxyprogesterone is reported as an ingredient of Dépo-Prodasone in the following countries:

• Tunisia

Medroxyprogesterone 17α-acetate (a derivative of Medroxyprogesterone) is reported as an ingredient of Dépo-Prodasone in the following countries:

• France

International Drug Name Search

Potasion

Potasion may be available in the countries listed below.

Ingredient matches for Potasion

Potassium Chloride

Potassium Chloride is reported as an ingredient of Potasion in the following countries:

• Spain

International Drug Name Search

Epirubicina Delta Farma

Epirubicina Delta Farma may be available in the countries listed below.

Ingredient matches for Epirubicina Delta Farma

Epirubicin

Epirubicin hydrochloride (a derivative of Epirubicin) is reported as an ingredient of Epirubicina Delta Farma in the following countries:

• Argentina

International Drug Name Search

Zitrol XR

Zitrol XR may be available in the countries listed below.

Ingredient matches for Zitrol XR

Glipizide

Glipizide is reported as an ingredient of Zitrol XR in the following countries:

• Bangladesh

International Drug Name Search